Jupiter Neurosciences, Inc. SEC filings JUNS
Jupiter Neurosciences, Inc. has 203 filings in SEC EDGAR's recent list, going back to Jul 15, 2016. Its latest annual report, Form ARS, was filed on Jun 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 3, 2026 (bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 26, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 22, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 28, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 28, 2026 | — |
| 4 | Insider transaction | Aug 5, 2026 | Jul 31, 2026 |
| 3 | Initial insider ownership | Jul 22, 2026 | Jul 22, 2026 |
| 4 | Insider transaction | Jul 13, 2026 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 13, 2026 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 13, 2026 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 13, 2026 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 13, 2026 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 26, 2026 |
| 3 | Initial insider ownership | Jul 1, 2026 | Jun 26, 2026 |
| 4 | Insider transaction | Jun 5, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jun 4, 2026 | Jun 2, 2026 |
| 4 | Insider transaction | Jul 7, 2025 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 7, 2025 | Jul 2, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 3, 2025 | Jul 1, 2025 |
| 4 | Insider transaction | Jul 1, 2025 | Jun 2, 2025 |
| 4 | Insider transaction | Jul 1, 2025 | Jun 2, 2025 |
| 4 | Insider transaction | Jan 24, 2025 | Jan 22, 2025 |
| 4 | Insider transaction | Jan 24, 2025 | Jan 22, 2025 |
| SC 13D | Ownership over 5% (active) | Nov 15, 2024 | — |
| SC 13D | Ownership over 5% (active) | Nov 15, 2024 | — |
| SC 13D | Ownership over 5% (active) | Nov 15, 2024 | — |
| SC 13D | Ownership over 5% (active) | Nov 15, 2024 | — |
| SC 13D | Ownership over 5% (active) | Nov 15, 2024 | — |
| 3 | Initial insider ownership | Nov 13, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
| 3 | Initial insider ownership | Nov 8, 2024 | Nov 8, 2024 |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JUNS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Jupiter, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1679628
- Former names
- Jupiter Orphan Therapeutics, Inc. (until Dec 5, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.